Fludarabine
Mesothelin-positive Advanced Malignant Solid Tumors
Zhejiang UniversitySmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the Mesothelin-positive Advanced Malignant Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Anti-Mesothelin Car-T Cells Zhejiang University | Phase 1 | CC |
ct-95 Context Therapeutics Inc. | Phase 1 | CC |
Uclm802 Cell Zhejiang University | Phase 1 | CC |
Cyclophosphamide Zhejiang University | N/A | D |
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →